Anti-Mouse CD29 [Clone KMI6] – Purified in vivo GOLD™ Functional Grade

In Vivo Applications of Clone KMI6 (Anti-Mouse CD29/Integrin β1) in Mice

Clone KMI6 is a rat monoclonal antibody that specifically targets mouse CD29, also known as integrin β1, a widely expressed cell surface protein involved in adhesion, signaling, and tissue organization. In vivo, KMI6 is primarily used for functional studies targeting the CD29/integrin β1 pathway in mice.

Functional Neutralization Studies

In vivo CD29 neutralization is a major application of KMI6. By administering this antibody to mice, researchers can block CD29-mediated functions, which are critical for cell adhesion, migration, and signaling processes in various tissues. This approach is used to investigate the role of integrin β1 in physiological and pathological contexts, such as inflammation, wound healing, and immune cell trafficking.

Disease Models

Collagen-induced arthritis: In one documented example, KMI6 antibody was administered intraperitoneally (i.p.) to mice with collagen-induced arthritis. The treatment ameliorated joint swelling and cartilage erosion, demonstrating the therapeutic potential of CD29 blockade in autoimmune and inflammatory diseases. This suggests that KMI6 can be used to model and test interventions for conditions where integrin signaling is dysregulated.

Basic Research Applications

Leukocyte and Stromal Cell Studies: KMI6 recognizes an epitope that is widely distributed but may have restricted surface expression within lymphohematopoietic tissues in vivo. This property makes it useful for studying integrin β1’s role in the development and function of immune and stromal cells.

Cell Trafficking and Tissue Repair: Since CD29 pairs with various α integrins to form heterodimers involved in cell-extracellular matrix interactions, KMI6 can be used to study processes like leukocyte recruitment, tissue repair, and epithelial-mesenchymal interactions in vivo.

Technical Specifications for In Vivo Use

• Isotype: Rat IgG2a, κ.
• Formulation: Typically provided in PBS, pH 7.0, with low endotoxin levels suitable for in vivo injection.
• Administration: Common routes include intraperitoneal injection, with dosage and frequency tailored to the experimental design.
• Controls: Recommended to use an appropriate isotype control (e.g., InVivoMAb rat IgG2a isotype control).

Summary Table: Key In Vivo Uses of Clone KMI6

Conclusion

Clone KMI6 is a versatile tool for in vivo studies in mice, enabling functional blockade of CD29/integrin β1 to investigate its role in immunity, inflammation, tissue repair, and disease pathogenesis. Its low endotoxin formulation and well-characterized reactivity make it suitable for a range of experimental applications requiring in vivo modulation of integrin signaling pathways.

In the literature, the KMI6 antibody, which targets mouse CD29 (Integrin beta 1), is often used in conjunction with other antibodies and proteins to study various biological processes. Here are some commonly used antibodies and proteins mentioned alongside KMI6:

1. Anti-CD49a to CD49f Antibodies: These antibodies target the alpha subunits that form non-covalent bonds with CD29 (Integrin beta 1) to form VLA-1 through VLA-6 heterodimers. They are used to study the role of these integrins in cell adhesion and migration.

2. VCAM-1 and MadCAM-1 Antibodies:These cellular receptors interact with some CD29-containing integrins and are used to study cell adhesion and immune responses.

3. TRPV4 Agonists (e.g., GSK1016790A):These agonists are used in studies examining the relationship between TRPV4 and beta 1 integrin-mediated cell-matrix adhesions.

Other proteins and antibodies that are not specifically mentioned alongside KMI6 but are relevant in similar contexts include:

• CD51 (Alpha V Integrin): This protein forms heterodimers with CD29 and is involved in cell adhesion processes.
• Fibronectin and other ECM Proteins: These proteins are crucial for studying integrin-mediated adhesion and are often used in assays with KMI6.

These antibodies and proteins are used in various applications like flow cytometry, immunohistochemistry, and functional assays to investigate cell adhesion, trafficking, and differentiation processes.

The monoclonal antibody clone KMI6 is widely used in scientific literature as a reagent targeting mouse CD29 (integrin β1), a protein essential for cell-matrix adhesions, migration, and signaling in various cell types. Key findings from citations and applications of clone KMI6 include:

• Identification and quantification of β1 integrin expression: KMI6 specifically recognizes integrin β1 on the cell surface, making it a standard tool in flow cytometry, immunofluorescence, and cell sorting to profile expression or localization of β1 integrin in diverse mouse tissues and cell lines.

• Functional studies in cell adhesion and migration: Studies have used KMI6 to investigate the role of β1 integrin in cell-matrix adhesion, spreading, and migration. For example, in research on mouse skin fibroblasts, KMI6 staining showed that TRPV4 regulates β1 integrin-mediated cell–matrix adhesion, and loss of TRPV4 disrupts integrin localization and function. Similar approaches have been used to study integrin-dependent cell migration and signaling on fibronectin or collagen.

• Role in immune cell function and activation: Immobilized KMI6 (as an agonistic antibody) has been shown to stimulate CD29 (integrin β1) signaling, enhancing downstream effects such as cytokine production (e.g., glutamate release from T cells upon KMI6 stimulation). This demonstrates the functional impact of β1 integrin engagement on immune cells.

• Modulating differentiation pathways: KMI6 has been used to demonstrate that β1 integrin ligation enhances granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced differentiation of certain myeloid cell populations (e.g., higher aldehyde dehydrogenase activity), indicating a link between extracellular matrix binding and cell fate specification.

• Broad application across cell types: Clone KMI6 has been validated on leukocytes, endothelial cells, smooth muscle, and epithelial cells, highlighting its reliability across experimental systems for murine β1 integrin detection.

Summary Table: Principal Uses of Clone KMI6

No major controversies or conflicting reports were identified regarding KMI6 specificity or function, and it is cited as a key validated reagent in multiple peer-reviewed studies for its targeted recognition of mouse β1 integrin.

The dosing regimen for clone KMI6 in mouse models is most commonly reported as 10 mg/kg via intraperitoneal (i.p.) injection when used for in vivo applications such as inhibition of MMP-9 following myocardial infarction (MI). There is limited direct evidence of other dosing regimens for KMI6 across different mouse models in the available literature, and most sources reference a similar or identical approach.

Essential context:

• Standard regimen: The antibody is administered at 10 mg/kg i.p. in published studies focused on cardiac injury and matrix metalloproteinase inhibition.
• Reported applications: Experimental contexts for KMI6 include blocking CD29 (integrin β1) function in vivo, with readouts often centering on cellular adhesion, trafficking, proliferation, differentiation, or inhibition of specific downstream effects.
• Dilution and storage: KMI6 is typically supplied unconjugated and formulated in PBS at pH 7.0, and storage is recommended at 4°C.

Additional relevant information:

• CD29 expression: This integrin is widely present on leukocytes, endothelial, smooth muscle, and epithelial cells, forming heterodimers involved in diverse physiological and pathological processes.
• No evidence of major dose variation: Based on available data, there is no consistent reporting of alternative dosing regimens (such as higher/lower doses, different injection routes, or dosing intervals) for KMI6 in distinct mouse models. Most cited studies use the same regimen regardless of disease context (e.g., cardiac vs immunological disease).
• Contrast with other antibodies: By comparison, other in vivo antibodies show more diverse dosing schedules (e.g., anti-CD3 at 5–50 μg i.v., anti-NK1.1 at 200–300 μg i.p.), but this breadth is not documented for KMI6.

In summary, 10 mg/kg i.p. is the standard KMI6 dose reported for mouse studies, and current literature does not describe substantial variation across different disease models or mouse strains. If you need details about other dosing regimens or specific mouse strains, additional targeted study results may be required.